Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4149-4153

  Kontou, Paschalina ^a   Chatzika, Kalliopi ^a   Pitsiou, Georgia ^b   Stanopoulos, Ioannis ^b   Argyropoulou Pataka, Paraskevi ^b   Kioumis, Ioannis ^b  

^a G Papanikolaou Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; BRONCHUS SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STEADY STATE;

ANTI-INFECTIVE AGENTS; BRONCHI; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CRITICAL ILLNESS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL;

EID: 80051816333     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00566-10     Document Type: Article

References (37)

1. Baldwin, D R, D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents: Methodological considerations. Antimicrob. Agents Chemother. 36:1171-1175.
2. Balter, M S, et al. 2003. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl.):3B-32B. (Pubitemid 37192994)
3. Begg, E J, et al. 2000. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. Br. J. Clin. Pharmacol. 49:32-38. (Pubitemid 30050484)
4. Berré, J., J P Thys, M. Husson, D. Gangji, and J. Klastersky. 1988. Penetration of ciprofloxacin in bronchial secretions after intravenous administration. J. Antimicrob. Chemother. 22:499-504. (Pubitemid 18264818)
5. Beskid, G, and B L Prosser. 1993. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: An interim report from 27 centers. Am. J. Med. 94:2S-8S. (Pubitemid 23089423)
6. Canut, A., J E Martín-Herrero, A. Labora, and H. Maortua. 2007. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 60:605-612. (Pubitemid 47299876)
7. Celli, B R, W. MacNee, and ATS/ERS Task Force. 2004. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur. Respir. J. 23:932-946. (Pubitemid 38807371)
8. Cockcroft, D W, and M H Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
9. Decré, D, and E. Bergogne-Bérézin. 1993. Pharmacokinetics of quinolones with special reference to the respiratory tree. J. Antimicrob. Chemother. 31:331-343. (Pubitemid 23110674)
10. Drusano, G L, D E Johnson, M. Rosen, and H C Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490. (Pubitemid 23072592)
11. Eller, J., et al. 1998. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 113:1542-1548. (Pubitemid 28307157)
12. Forrest, A., et al. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081. (Pubitemid 23141323)
13. Garrelts, J C, G. Jost, S F Kowalsky, G J Krol, and J T Lettieri. 1996. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 40:1153-1156. (Pubitemid 26136026)
14. Gotfried, M H, L H Danziger, and K A Rodvold. 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122. (Pubitemid 32679439)
15. Halbert, R J, et al. 2006. Global burden of COPD: Systematic review and meta-analysis. Eur. Respir. J. 28:523-532. (Pubitemid 44794666)
16. Imre, S., M T Dogaru, C E Vari, T. Muntean, and L. Kelemen. 2003. Validation of an HPLC method for the determination of ciprofloxacin in human plasma. J. Pharm. Biomed. Anal. 33:125-130. (Pubitemid 37303946)
17. Kuti, J L, C H Nightingale, and D P Nicolau. 2004. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob. Agents Chemother. 48:2464-2470. (Pubitemid 38823411)
18. Lacy, M K, et al. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677. (Pubitemid 29109538)
19. Lettieri, J T, M C Rogge, L. Kaiser, R M Echols, and A H Heller. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993-996.
20. Lipman, J., et al. 1998. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob. Agents Chemother. 42:2235-2239. (Pubitemid 28420356)
21. Lockhart, S R, et al. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359. (Pubitemid 47585661)
22. Montgomery, M J, et al. 2001. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:3468-3473. (Pubitemid 33107864)
23. Pea, F., D. Poz, P. Viale, F. Pavan, and M. Furlanut. 2006. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J. Antimicrob. Chemother. 58:380-386. (Pubitemid 44294951)
24. Preston, S L, et al. 1998. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 279:125-129. (Pubitemid 28068302)
25. Rabe, K F, et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176:532-555. (Pubitemid 47403272)
26. Roberts, J A, and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
27. Saux, P., et al. 1994. Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. Antimicrob. Agents Chemother. 38:901-904. (Pubitemid 24114043)
28. Scaglione, F, and L. Paraboni. 2008. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: Setting appropriate dosing regimens. Int. J. Antimicrob. Agents 32:294-301.
29. Schüler, P., et al. 1997. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur. Respir. J. 10:1130-1136. (Pubitemid 27201821)
30. Shah, A., J. Lettieri, D. Nix, J. Wilton, and A H Heller. 1995. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob. Agents Chemother. 39:1003-1006.
31. Soler, N., et al. 1998. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 157:1498-1505.
32. Thomas, J K, et al. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527. (Pubitemid 28114802)
33. Valcke, Y., R. Pauwels, and M. Van der Straeten. 1990. Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. 3:715-722. (Pubitemid 20228711)
34. Van Zanten, A R H, et al. 2008. Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study. J. Crit. Care 23:422-430.
35. WHO. 2008. WHO, Geneva, Switzerland. Who.int/mediacentre/factsheets/ fs310/en/index.html.
36. Woodhead, M., et al. 2005. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26:1138-1180. (Pubitemid 41829947)
37. Zelenitsky, S., R. Ariano, G. Harding, and A. Forrest. 2005. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob. Agents Chemother. 49:4009-4014. (Pubitemid 41400939)